Home Reports Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market is segmented by Drug Type (Anti-Fibrotic Medication, Corticosteroids, Immune Suppressing, Others), Route of Administration (Oral, Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region. Forecast for 2026 to 2036.

Historical Data Covered: 2016 to 2024 | Base Year: 2025 | Estimated Year: 2026 | Forecast Period: 2027 to 2036

Methodology

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

  • Demand and Growth Drivers
    • PF-ILD indication approval has expanded antifibrotic treatment access beyond IPF.
    • Progressive phenotype recognition is increasing the eligible patient population.
    • Multidisciplinary team expansion is improving diagnostic accuracy.
  • Product and Segment View
    • Anti-fibrotic medications are expected to lead with 47.0% of drug type demand in 2026.
    • Oral administration is expected to represent 53.0% of route demand.
    • Hospital pharmacies are expected to account for 41.0% of distribution.
  • Geography and Competitive Outlook
    • South Korea (6.4%) and Japan (6.3%) are expected to lead growth.
    • The USA (6.1%) maintains growth through FDA-approved indication.
    • Companies with PF-ILD specific approval are expected to maintain dominant positions.
  • Analyst Opinion
    • The PF-ILD market represents a significant indication expansion for antifibrotic therapy beyond IPF.
    • Nintedanib holds the dominant position through INBUILD evidence and specific approval.
    • The market benefits from growing phenotype-based treatment recognition.
    • Companies with PF-ILD approval and established prescribing infrastructure are expected to maintain leadership.

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Value Analysis

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Definition

The PF-ILD treatment market covers antifibrotic pharmaceutical treatments and supportive care for managing progressive fibrosing ILD, a clinical phenotype encompassing multiple ILD subtypes that exhibit progressive fibrosis despite standard management.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Inclusions

Market scope covers all commercially available PF-ILD treatments categorized by drug type (anti-fibrotic medication, immunosuppressants, corticosteroids, supportive therapies), route of administration (oral, inhaled, intravenous), distribution channel (hospital pharmacies, retail pharmacies, specialty pharmacies), and patient group (IPF-derived PF-ILD, autoimmune ILD-derived, exposure-related, unclassifiable). Revenue coverage spans 2026 to 2036.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Exclusions

The scope does not include treatments for non-progressive ILD, general respiratory infection management, or lung transplantation surgical costs.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Research Methodology

  • Primary Research: FMI analysts conducted interviews with pulmonologists, ILD centre directors, and specialty pharmacy managers.
  • Desk Research: Combined data from ILD patient registries, pharmaceutical prescription databases, and respiratory treatment records.
  • Market Sizing and Forecasting: Bottom-up sizing across drug type, route of administration, and patient group segments with regional ILD diagnosis rate curves.
  • Data Validation: Cross-checked quarterly against ILD registry data, pharmaceutical sales, and respiratory clinic utilization.

Why is the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Growing?

  • Regulatory approval of nintedanib for progressive fibrosing ILD based on INBUILD has established antifibrotic access beyond IPF.
  • Growing clinical recognition of the progressive fibrosing phenotype across ILD subtypes is increasing the eligible patient population.
  • Expansion of multidisciplinary ILD teams is improving diagnostic accuracy and treatment decisions.

Demand reflects the clinical recognition that progressive fibrosis occurs across multiple ILD subtypes and that antifibrotic therapy provides benefit regardless of underlying diagnosis. The INBUILD trial demonstrated nintedanib efficacy across a range of diagnoses.

Adoption of anti-fibrotic medication leads at 47.0%, driven by nintedanib regulatory approval for PF-ILD expanding the eligible patient population.

Pricing reflects specialty pharmaceutical positioning consistent with IPF treatment pricing, with the broader population creating a larger addressable market.

Market Segmentation Analysis

  • Anti-Fibrotic Medication accounts for 47.0% of the drug type segment.
  • Oral represents 53.0% of the route of administration segment.
  • Hospital Pharmacies leads the distribution channel segment with 41.0% share.

The PF-ILD treatment market is segmented by drug type, route of administration, distribution channel, and patient group. Demand reflects the phenotype-based treatment approach extending antifibrotic therapy across multiple ILD diagnoses exhibiting progressive fibrosis.

Insights into the Anti-Fibrotic Medication Drug Type Segment

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Analysis By Drug Type

Anti-fibrotic medications lead at 47.0% due to INBUILD trial evidence supporting nintedanib efficacy across the progressive fibrosing phenotype, approximately doubling the addressable patient population beyond IPF.

Insights into the Oral Route of Administration Segment

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Analysis By Route Of Administration

Oral administration represents 53.0% of route demand, reflecting oral nintedanib and pirfenidone formulations enabling outpatient chronic treatment.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Drivers, Restraints, and Opportunities

  • Regulatory and structural demand drivers are creating sustained procurement patterns.
  • Cost and access constraints create segmentation in adoption rates.
  • Technology and product development are expanding the addressable market.

The progressive fibrosing interstitial lung disease (pf-ild) treatment market is shaped by regulatory, technology, and procurement dynamics.

PF-ILD Indication Approval

Demand is shaped by nintedanib regulatory approval for progressive fibrosing ILD, extending treatment access beyond IPF.

Progressive Phenotype Recognition

Growth reflects growing clinical recognition that progressive fibrosis is treatable across ILD subtypes.

Multidisciplinary ILD Team Expansion

Adoption is supported by expanding MDT approaches that improve diagnostic accuracy.

Established Antifibrotic Framework

The existing IPF treatment infrastructure provides a ready framework for extending therapy to PF-ILD.

Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market By Key Countries

Top Country Growth Comparison Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Cagr (2026 2036)

Country CAGR
South Korea 6.4%
Japan 6.3%
USA 6.2%
EU 6.1%
UK 5.8%

Source: FMI analysis based on primary research and proprietary forecasting model

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Cagr Analysis By Country

  • South Korea leads with 6.4% CAGR.
  • Japan at 6.3% reflects expanding capabilities.
  • USA (6.2%) and EU (6.1%) maintain steady growth.

The global progressive fibrosing interstitial lung disease (pf-ild) treatment market is expected to grow at 6.0% per year from 2026 to 2036.

Demand Outlook for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in South Korea

South Korea is expected to grow at 6.4% through 2036, supported by respiratory medicine advancement and PF-ILD diagnostic recognition.

  • Respiratory medicine supports specialist treatment.
  • PF-ILD recognition increases identified patients.
  • Antifibrotic adoption is growing.

Future Outlook for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in Japan

Japan is expected to grow at 6.3% through 2036, driven by established ILD infrastructure and antifibrotic prescribing experience.

  • ILD infrastructure provides specialist management.
  • Antifibrotic prescribing experience supports adoption.
  • Clinical research advances understanding.

Opportunity Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in the United States

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Country Value Analysis

The USA is expected to grow at 6.1% through 2036, driven by FDA-approved PF-ILD indication and established ILD specialist networks.

  • FDA-approved indication enables access.
  • ILD specialist networks provide prescribing expertise.
  • Specialty pharmacy supports distribution.

In-depth Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in the European Union

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Europe Country Market Share Analysis, 2026 & 2036

The EU is expected to grow at 6.0% through 2036, supported by EMA-approved PF-ILD indication and respiratory research.

  • EMA approval enables treatment across member states.
  • Research collaboration advances evidence.
  • MDT expansion improves decision-making.

Sales Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in the United Kingdom

The UK is expected to grow at 5.8% through 2036, supported by NICE evaluation and NHS specialist respiratory services.

  • NICE evaluation guides access decisions.
  • NHS respiratory services deliver specialist care.
  • MDT development improves diagnostics.

Competitive Landscape and Strategic Positioning

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Analysis By Company

  • Boehringer Ingelheim leads with an estimated 37.2% market share.
  • The competitive landscape includes global and specialized players.
  • Entry barriers include regulatory, relationship, and scale factors.

Boehringer Ingelheim leads through Ofev (nintedanib), the only antifibrotic with PF-ILD specific regulatory approval.

Roche Holding AG maintains a position through pirfenidone used off-label in some PF-ILD settings.

Bristol-Myers Squibb and FibroGen compete on antifibrotic pipeline development.

Entry barriers include the dominant nintedanib position, high trial costs, and specialist prescribing relationships.

Key Companies in the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Key global companies leading the progressive fibrosing interstitial lung disease (pf-ild) treatment market include:

  • Boehringer Ingelheim (Germany) and Roche Holding AG (Switzerland) hold dominant positions through approved antifibrotics.
  • Bristol-Myers Squibb (USA) and FibroGen, Inc. (USA) compete on pipeline development.
  • Galapagos NV (Belgium), Pliant Therapeutics (USA), and Blade Therapeutics (USA) represent emerging positions.

Competitive Benchmarking: Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Company PF-ILD Approval Clinical Evidence Specialist Relationships Geographic Reach
Boehringer Ingelheim Strong Strong Strong Global
Roche Holding AG Moderate Strong Strong Global
Bristol-Myers Squibb Low Moderate Strong Global
FibroGen, Inc. Low Moderate Moderate N. America, Global
Galapagos NV Low Low Moderate Europe
Pliant Therapeutics Low Low Low N. America

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

  • In 2025, Boehringer Ingelheim announced that its Phase 3 FIBRONEER™-ILD trial for the novel antifibrotic nerandomilast successfully met its primary endpoint.
  • In 2025, the PF-ILD market saw continued focus on novel therapeutic pipeline development, with multiple companies initiating or advancing clinical trials for new molecules targeting fibrotic pathways.

Key Players in the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Major Global Players

  • Boehringer Ingelheim
  • Roche Holding AG
  • Bristol-Myers Squibb
  • FibroGen, Inc.
  • Galapagos NV
  • Verona Pharma
  • Genentech (a Roche subsidiary)

Emerging Players/Startups

  • Galapagos NV
  • Pliant Therapeutics
  • Blade Therapeutics
  • Samumed
  • Kiniksa Pharmaceuticals

Report Scope and Coverage

Progressive Fibrosing Interstitial Lung Disease (pf Ild) Treatment Market Breakdown By Drug Type, Route Of Administration, And Region

Parameter Details
Quantitative Units USD 5.67 billion to USD 10.15 billion, at a CAGR of 6.0%
Market Definition The PF-ILD treatment market covers antifibrotic pharmaceutical treatments and supportive care for managing progressive fibrosing ILD, a clinical phenotype encompassing multiple ILD subtypes that exhibit progressive fibrosis despite standard management.
Regions Covered North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled Boehringer Ingelheim, Roche Holding AG, Bristol-Myers Squibb, FibroGen, Inc., Galapagos NV, Verona Pharma, Genentech (a Roche subsidiary), Sanofi, Gilead Sciences, AstraZeneca
Forecast Period 2026 to 2036
Approach Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Drug Type:

  • Anti-Fibrotic Medication
  • Corticosteroids
  • Immune Suppressing
  • Others

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Route of Administration:

  • Oral
  • Injectable

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Patient Group:

  • Idiopathic Pulmonary Fibrosis-Derived PF-ILD
  • Connective Tissue Disease-Associated PF-ILD
  • Hypersensitivity Pneumonitis-Derived PF-ILD
  • Unclassifiable Interstitial Lung Disease

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market by Region:

  • North America
    • USA
    • Canada
    • Mexico
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Western Europe
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • Nordic
    • BENELUX
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Hungary
    • Balkan & Baltic
    • Rest of Eastern Europe
  • East Asia
    • China
    • Japan
    • South Korea
  • South Asia and Pacific
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of South Asia and Pacific
  • Middle East & Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkiye
    • South Africa
    • Other African Union
    • Rest of Middle East & Africa

Research Sources and Bibliography

  • 1. American Thoracic Society. (2025). ATS Guidelines: PF-ILD. ATS.
  • 2. European Respiratory Society. (2024). ERS Statement on PF-ILD. ERS.
  • 3. USA Food and Drug Administration. (2025). FDA Approved: Nintedanib for PF-ILD. FDA.
  • 4. National Institute for Health and Care Excellence. (2024). NICE Appraisal: Nintedanib for PF-ILD. NICE.
  • 5. World Health Organization. (2024). WHO Classification of ILD. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

  • Estimating the market size and revenue from 2026 to 2036.
  • Segmentation by drug type, route of administration, distribution channel, and patient group.
  • Regional and country-level insights across more than 30 markets.
  • INBUILD evidence and clinical adoption analysis.
  • Competitive landscape assessment.
  • Investment opportunity identification.
  • Treatment protocol and phenotype-based prescribing analysis.
  • Data delivery in PDF and Excel formats.

Frequently Asked Questions

What is the global market demand for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment in 2026?

In 2026, the global market is expected to be worth USD 5.67 billion.

How big will the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market be in 2036?

By 2036, the market is expected to be worth USD 10.15 billion.

How much is demand expected to grow between 2026 and 2036?

Between 2026 and 2036, demand is expected to grow at a CAGR of 6.0%.

Which Drug Type segment is expected to lead in 2026?

Anti-Fibrotic Medication is expected to account for 47.0% of the segment in 2026.

What is causing demand to rise in South Korea?

South Korea is expected to grow at 6.4% through 2036.

What is causing demand to rise in Japan?

Japan is expected to grow at 6.3% through 2036.

What does this report mean by Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market definition?

The PF-ILD treatment market covers antifibrotic pharmaceutical treatments and supportive care for managing progressive fibrosing ILD, a clinical phenotype encompassing multiple ILD subtypes that exhib.

How does FMI make the forecast?

Forecasting uses a hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Table of Content

  1. Executive Summary
    • Global Market Outlook
    • Demand to side Trends
    • Supply to side Trends
    • Technology Roadmap Analysis
    • Analysis and Recommendations
  2. Market Overview
    • Market Coverage / Taxonomy
    • Market Definition / Scope / Limitations
  3. Research Methodology
    • Chapter Orientation
    • Analytical Lens and Working Hypotheses
      • Market Structure, Signals, and Trend Drivers
      • Benchmarking and Cross-market Comparability
      • Market Sizing, Forecasting, and Opportunity Mapping
    • Research Design and Evidence Framework
      • Desk Research Programme (Secondary Evidence)
        • Company Annual and Sustainability Reports
        • Peer-reviewed Journals and Academic Literature
        • Corporate Websites, Product Literature, and Technical Notes
        • Earnings Decks and Investor Briefings
        • Statutory Filings and Regulatory Disclosures
        • Technical White Papers and Standards Notes
        • Trade Journals, Industry Magazines, and Analyst Briefs
        • Conference Proceedings, Webinars, and Seminar Materials
        • Government Statistics Portals and Public Data Releases
        • Press Releases and Reputable Media Coverage
        • Specialist Newsletters and Curated Briefings
        • Sector Databases and Reference Repositories
        • FMI Internal Proprietary Databases and Historical Market Datasets
        • Subscription Datasets and Paid Sources
        • Social Channels, Communities, and Digital Listening Inputs
        • Additional Desk Sources
      • Expert Input and Fieldwork (Primary Evidence)
        • Primary Modes
          • Qualitative Interviews and Expert Elicitation
          • Quantitative Surveys and Structured Data Capture
          • Blended Approach
        • Why Primary Evidence is Used
        • Field Techniques
          • Interviews
          • Surveys
          • Focus Groups
          • Observational and In-context Research
          • Social and Community Interactions
        • Stakeholder Universe Engaged
          • C-suite Leaders
          • Board Members
          • Presidents and Vice Presidents
          • R&D and Innovation Heads
          • Technical Specialists
          • Domain Subject-matter Experts
          • Scientists
          • Physicians and Other Healthcare Professionals
        • Governance, Ethics, and Data Stewardship
          • Research Ethics
          • Data Integrity and Handling
      • Tooling, Models, and Reference Databases
    • Data Engineering and Model Build
      • Data Acquisition and Ingestion
      • Cleaning, Normalisation, and Verification
      • Synthesis, Triangulation, and Analysis
    • Quality Assurance and Audit Trail
  4. Market Background
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
      • Trends
    • Scenario Forecast
      • Demand in Optimistic Scenario
      • Demand in Likely Scenario
      • Demand in Conservative Scenario
    • Opportunity Map Analysis
    • Product Life Cycle Analysis
    • Supply Chain Analysis
    • Investment Feasibility Matrix
    • Value Chain Analysis
    • PESTLE and Porter’s Analysis
    • Regulatory Landscape
    • Regional Parent Market Outlook
    • Production and Consumption Statistics
    • Import and Export Statistics
  5. Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
    • Historical Market Size Value (USD Million) Analysis, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
      • Y to o to Y Growth Trend Analysis
      • Absolute $ Opportunity Analysis
  6. Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
  7. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Drug Type
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Drug Type , 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Drug Type , 2026 to 2036
      • Anti-Fibrotic Medication
      • Corticosteroids
      • Immune Suppressing
      • Others
    • Y to o to Y Growth Trend Analysis By Drug Type , 2021 to 2025
    • Absolute $ Opportunity Analysis By Drug Type , 2026 to 2036
  8. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Route of Administration
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Route of Administration, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Route of Administration, 2026 to 2036
      • Oral
      • Injectable
    • Y to o to Y Growth Trend Analysis By Route of Administration, 2021 to 2025
    • Absolute $ Opportunity Analysis By Route of Administration, 2026 to 2036
  9. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Distribution Channel
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Distribution Channel, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Distribution Channel, 2026 to 2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Y to o to Y Growth Trend Analysis By Distribution Channel, 2021 to 2025
    • Absolute $ Opportunity Analysis By Distribution Channel, 2026 to 2036
  10. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Patient Group
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Patient Group, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Patient Group, 2026 to 2036
      • Idiopathic Pulmonary Fibrosis-Derived PF-ILD
      • Connective Tissue Disease-Associated PF-ILD
      • Hypersensitivity Pneumonitis-Derived PF-ILD
      • Unclassifiable Interstitial Lung Disease
    • Y to o to Y Growth Trend Analysis By Patient Group, 2021 to 2025
    • Absolute $ Opportunity Analysis By Patient Group, 2026 to 2036
  11. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
    • Introduction
    • Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
    • Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
      • North America
      • Latin America
      • Western Europe
      • Eastern Europe
      • East Asia
      • South Asia and Pacific
      • Middle East & Africa
    • Market Attractiveness Analysis By Region
  12. North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • USA
        • Canada
        • Mexico
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Market Attractiveness Analysis
      • By Country
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Key Takeaways
  13. Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Brazil
        • Chile
        • Rest of Latin America
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Market Attractiveness Analysis
      • By Country
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Key Takeaways
  14. Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Germany
        • UK
        • Italy
        • Spain
        • France
        • Nordic
        • BENELUX
        • Rest of Western Europe
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Market Attractiveness Analysis
      • By Country
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Key Takeaways
  15. Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Russia
        • Poland
        • Hungary
        • Balkan & Baltic
        • Rest of Eastern Europe
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Market Attractiveness Analysis
      • By Country
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Key Takeaways
  16. East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • China
        • Japan
        • South Korea
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Market Attractiveness Analysis
      • By Country
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Key Takeaways
  17. South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • India
        • ASEAN
        • Australia & New Zealand
        • Rest of South Asia and Pacific
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Market Attractiveness Analysis
      • By Country
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Key Takeaways
  18. Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Kingdom of Saudi Arabia
        • Other GCC Countries
        • Turkiye
        • South Africa
        • Other African Union
        • Rest of Middle East & Africa
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Market Attractiveness Analysis
      • By Country
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
    • Key Takeaways
  19. Key Countries Market Analysis
    • USA
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Canada
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Mexico
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Brazil
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Chile
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Germany
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • UK
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Italy
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Spain
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • France
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • India
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • ASEAN
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Australia & New Zealand
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • China
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Japan
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • South Korea
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Russia
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Poland
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Hungary
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Kingdom of Saudi Arabia
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • Turkiye
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
    • South Africa
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Drug Type
        • By Route of Administration
        • By Distribution Channel
        • By Patient Group
  20. Market Structure Analysis
    • Competition Dashboard
    • Competition Benchmarking
    • Market Share Analysis of Top Players
      • By Regional
      • By Drug Type
      • By Route of Administration
      • By Distribution Channel
      • By Patient Group
  21. Competition Analysis
    • Competition Deep Dive
      • Boehringer Ingelheim
        • Overview
        • Product Portfolio
        • Profitability by Market Segments (Product/Age /Sales Channel/Region)
        • Sales Footprint
        • Strategy Overview
          • Marketing Strategy
          • Product Strategy
          • Channel Strategy
      • Roche Holding AG
      • Bristol-Myers Squibb
      • FibroGen, Inc.
      • Galapagos NV
      • Verona Pharma
      • Genentech (a Roche subsidiary)
      • Sanofi
      • Gilead Sciences
      • AstraZeneca
  22. Assumptions & Acronyms Used

List of Tables

  • Table 1: Global Market Value (USD Million) Forecast by Region, 2021 to 2036
  • Table 2: Global Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 3: Global Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 4: Global Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 5: Global Market Value (USD Million) Forecast by Patient Group, 2021 to 2036
  • Table 6: North America Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 7: North America Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 8: North America Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 9: North America Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 10: North America Market Value (USD Million) Forecast by Patient Group, 2021 to 2036
  • Table 11: Latin America Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 12: Latin America Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 13: Latin America Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 14: Latin America Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 15: Latin America Market Value (USD Million) Forecast by Patient Group, 2021 to 2036
  • Table 16: Western Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 17: Western Europe Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 18: Western Europe Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 19: Western Europe Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 20: Western Europe Market Value (USD Million) Forecast by Patient Group, 2021 to 2036
  • Table 21: Eastern Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 22: Eastern Europe Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 23: Eastern Europe Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 24: Eastern Europe Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 25: Eastern Europe Market Value (USD Million) Forecast by Patient Group, 2021 to 2036
  • Table 26: East Asia Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 27: East Asia Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 28: East Asia Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 29: East Asia Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 30: East Asia Market Value (USD Million) Forecast by Patient Group, 2021 to 2036
  • Table 31: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 32: South Asia and Pacific Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 33: South Asia and Pacific Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 34: South Asia and Pacific Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 35: South Asia and Pacific Market Value (USD Million) Forecast by Patient Group, 2021 to 2036
  • Table 36: Middle East & Africa Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 37: Middle East & Africa Market Value (USD Million) Forecast by Drug Type , 2021 to 2036
  • Table 38: Middle East & Africa Market Value (USD Million) Forecast by Route of Administration, 2021 to 2036
  • Table 39: Middle East & Africa Market Value (USD Million) Forecast by Distribution Channel, 2021 to 2036
  • Table 40: Middle East & Africa Market Value (USD Million) Forecast by Patient Group, 2021 to 2036

List of Figures

  • Figure 1: Global Market Pricing Analysis
  • Figure 2: Global Market Value (USD Million) Forecast 2021-2036
  • Figure 3: Global Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 4: Global Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 5: Global Market Attractiveness Analysis by Drug Type
  • Figure 6: Global Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 7: Global Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 8: Global Market Attractiveness Analysis by Route of Administration
  • Figure 9: Global Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 10: Global Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 11: Global Market Attractiveness Analysis by Distribution Channel
  • Figure 12: Global Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 13: Global Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 14: Global Market Attractiveness Analysis by Patient Group
  • Figure 15: Global Market Value (USD Million) Share and BPS Analysis by Region, 2026 and 2036
  • Figure 16: Global Market Y-o-Y Growth Comparison by Region, 2026-2036
  • Figure 17: Global Market Attractiveness Analysis by Region
  • Figure 18: North America Market Incremental Dollar Opportunity, 2026-2036
  • Figure 19: Latin America Market Incremental Dollar Opportunity, 2026-2036
  • Figure 20: Western Europe Market Incremental Dollar Opportunity, 2026-2036
  • Figure 21: Eastern Europe Market Incremental Dollar Opportunity, 2026-2036
  • Figure 22: East Asia Market Incremental Dollar Opportunity, 2026-2036
  • Figure 23: South Asia and Pacific Market Incremental Dollar Opportunity, 2026-2036
  • Figure 24: Middle East & Africa Market Incremental Dollar Opportunity, 2026-2036
  • Figure 25: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 26: North America Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 27: North America Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 28: North America Market Attractiveness Analysis by Drug Type
  • Figure 29: North America Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 30: North America Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 31: North America Market Attractiveness Analysis by Route of Administration
  • Figure 32: North America Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 33: North America Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 34: North America Market Attractiveness Analysis by Distribution Channel
  • Figure 35: North America Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 36: North America Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 37: North America Market Attractiveness Analysis by Patient Group
  • Figure 38: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 39: Latin America Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 40: Latin America Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 41: Latin America Market Attractiveness Analysis by Drug Type
  • Figure 42: Latin America Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 43: Latin America Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 44: Latin America Market Attractiveness Analysis by Route of Administration
  • Figure 45: Latin America Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 46: Latin America Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 47: Latin America Market Attractiveness Analysis by Distribution Channel
  • Figure 48: Latin America Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 49: Latin America Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 50: Latin America Market Attractiveness Analysis by Patient Group
  • Figure 51: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 52: Western Europe Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 53: Western Europe Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 54: Western Europe Market Attractiveness Analysis by Drug Type
  • Figure 55: Western Europe Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 56: Western Europe Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 57: Western Europe Market Attractiveness Analysis by Route of Administration
  • Figure 58: Western Europe Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 59: Western Europe Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 60: Western Europe Market Attractiveness Analysis by Distribution Channel
  • Figure 61: Western Europe Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 62: Western Europe Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 63: Western Europe Market Attractiveness Analysis by Patient Group
  • Figure 64: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 65: Eastern Europe Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 66: Eastern Europe Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 67: Eastern Europe Market Attractiveness Analysis by Drug Type
  • Figure 68: Eastern Europe Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 69: Eastern Europe Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 70: Eastern Europe Market Attractiveness Analysis by Route of Administration
  • Figure 71: Eastern Europe Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 72: Eastern Europe Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 73: Eastern Europe Market Attractiveness Analysis by Distribution Channel
  • Figure 74: Eastern Europe Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 75: Eastern Europe Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 76: Eastern Europe Market Attractiveness Analysis by Patient Group
  • Figure 77: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 78: East Asia Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 79: East Asia Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 80: East Asia Market Attractiveness Analysis by Drug Type
  • Figure 81: East Asia Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 82: East Asia Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 83: East Asia Market Attractiveness Analysis by Route of Administration
  • Figure 84: East Asia Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 85: East Asia Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 86: East Asia Market Attractiveness Analysis by Distribution Channel
  • Figure 87: East Asia Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 88: East Asia Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 89: East Asia Market Attractiveness Analysis by Patient Group
  • Figure 90: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 91: South Asia and Pacific Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 92: South Asia and Pacific Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 93: South Asia and Pacific Market Attractiveness Analysis by Drug Type
  • Figure 94: South Asia and Pacific Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 95: South Asia and Pacific Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 96: South Asia and Pacific Market Attractiveness Analysis by Route of Administration
  • Figure 97: South Asia and Pacific Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 98: South Asia and Pacific Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 99: South Asia and Pacific Market Attractiveness Analysis by Distribution Channel
  • Figure 100: South Asia and Pacific Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 101: South Asia and Pacific Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 102: South Asia and Pacific Market Attractiveness Analysis by Patient Group
  • Figure 103: Middle East & Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 104: Middle East & Africa Market Value Share and BPS Analysis by Drug Type , 2026 and 2036
  • Figure 105: Middle East & Africa Market Y-o-Y Growth Comparison by Drug Type , 2026-2036
  • Figure 106: Middle East & Africa Market Attractiveness Analysis by Drug Type
  • Figure 107: Middle East & Africa Market Value Share and BPS Analysis by Route of Administration, 2026 and 2036
  • Figure 108: Middle East & Africa Market Y-o-Y Growth Comparison by Route of Administration, 2026-2036
  • Figure 109: Middle East & Africa Market Attractiveness Analysis by Route of Administration
  • Figure 110: Middle East & Africa Market Value Share and BPS Analysis by Distribution Channel, 2026 and 2036
  • Figure 111: Middle East & Africa Market Y-o-Y Growth Comparison by Distribution Channel, 2026-2036
  • Figure 112: Middle East & Africa Market Attractiveness Analysis by Distribution Channel
  • Figure 113: Middle East & Africa Market Value Share and BPS Analysis by Patient Group, 2026 and 2036
  • Figure 114: Middle East & Africa Market Y-o-Y Growth Comparison by Patient Group, 2026-2036
  • Figure 115: Middle East & Africa Market Attractiveness Analysis by Patient Group
  • Figure 116: Global Market - Tier Structure Analysis
  • Figure 117: Global Market - Company Share Analysis